Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report for Connecticut by County

Lung & Bronchus (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Rate
County
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate ascending
CI*Rank⋔
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
Connecticut 3 35.3 (34.5, 36.0) N/A 1,715 64.2
US (SEER+NPCR) 1 35.3 (35.2, 35.4) N/A 141,093 65.5
Windham County 7 48.6 (43.7, 53.9) 1 (1, 1) 76 68.2
New London County 7 41.7 (38.8, 44.8) 2 (2, 3) 158 67.2
Litchfield County 7 38.4 (35.2, 41.8) 3 (2, 6) 114 64.2
New Haven County 7 37.7 (36.1, 39.4) 4 (3, 6) 441 63.7
Tolland County 7 35.5 (31.8, 39.5) 5 (3, 7) 69 65.6
Hartford County 7 35.2 (33.7, 36.8) 6 (4, 7) 425 63.7
Middlesex County 7 34.2 (31.0, 37.8) 7 (3, 7) 87 61.2
Fairfield County 7 28.7 (27.4, 30.1) 8 (8, 8) 345 63.6
Notes:
Created by statecancerprofiles.cancer.gov on 03/19/2024 3:19 am.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.


1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
3 Source: SEER November 2022 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
7 Source: SEER November 2022 submission.
Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.

When displaying county information, the CI*Rank for the state is not shown because it's not comparable. To see the state CI*Rank please view the statistics at the US By State level.

Return to Top